Table 2.
CIN 3 + risk of different cytology results in HPV 16/18-positive women (n = 6533)
| HPV genotype | Cytology | CIN 3 + cases, No. (%) | Total | P Value |
|---|---|---|---|---|
| HPV 16 | NILM | 248 (11.4) | 2185 | < 0.001 |
| ASC-US | 268 (23.2) | 1157 | ||
| LSIL | 205 (28.8) | 713 | ||
| ASC-H | 211 (72.3) | 292 | ||
| AGC | 70 (66.0) | 106 | ||
| HSIL + | 623 (89.9) | 693 | ||
| HPV 18 | NILM | 38 (4.8) | 799 | < 0.001 |
| ASC-US | 40 (10.3) | 388 | ||
| LSIL | 23 (10.7) | 214 | ||
| ASC-H | 17 (34.7) | 49 | ||
| AGC | 36 (72.0) | 50 | ||
| HSIL + | 79 (82.3) | 96 |
HPV human papillomavirus, CIN 3 + cervical intraepithelial neoplasia grade 3 or more severe diagnoses, NILM negative for intraepithelial lesions or malignancy, ASC-US atypical squamous cells of undetermined significance, LSIL low-grade intraepithelial lesion, ASC-H atypical squamous cells cannot exclude high-grade squamous intraepithelial lesion, AGC atypical glandular cells, HSIL + high-grade squamous intraepithelial lesion or worse